Proleta Datta, MD
Neurology · Portland, ORNPI 1326393695
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Neurelis, Inc. accounts for 93.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $8,394 and has fallen 94.8% since, to $435 in 2025.
Across 34 payments — averaging $340.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$11K
- Neuropace, Inc.$320
- Jazz Pharmaceuticals Inc.$258
- Novartis$93
- Supernus Pharmaceuticals, Inc.$32
Across 1 payment — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$15K
What the payments were for
- Consulting fees$5,06044%
- Travel & lodging$4,56239%
- Food & beverage$1,94417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 26 | $10,863 |
| Neuropace, Inc. | 3 | $320 |
| Jazz Pharmaceuticals Inc. | 2 | $258 |
| Novartis | 1 | $93 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALTOCO$10,427
- RNS System$320
- Epidiolex$142
How this compares
$11,565 in reported general payments places this provider in the 85th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 30 | $125,093 |
| XcopriCenobamate | 38 | $60,707 |
| OnfiClobazam | 19 | $42,140 |
| BriviactBrivaracetam | 23 | $39,521 |
| AptiomEslicarbazepine Acetate | 22 | $38,873 |
| Oxtellar XrOxcarbazepine | 24 | $37,101 |
| Clobazam | 140 | $22,904 |
| Keppra XrLevetiracetam | 15 | $21,753 |
| VimpatLacosamide | 13 | $17,346 |
| FycompaPerampanel | 13 | $14,704 |
| Lacosamide | 173 | $13,135 |
| Lamotrigine ErLamotrigine | 35 | $9,407 |
| KeppraLevetiracetam | 12 | $9,354 |
| Topiramate ErTopiramate | 21 | $6,725 |
| Zonisamide | 81 | $4,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $32 | $37,10124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 228 neurology providers in Oregon.
Other neurology in Portland
- Kyle SmootPortland$932K
- Chafic KaramPortland$727K
- Herbert KrobPortland$416K
- Stanley CohanPortland$334K
- Matthew BrodskyPortland$123K
- Delaram SafarpourPortland$77K
- Kiren Kresa-ReahlPortland$71K
- Nizar ChahinPortland$57K
- Jeffrey KayePortland$54K
- Michelle CameronPortland$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.